His-Bundle vs Biventricular Pacing for Heart Failure
(HIS-CRT Trial)
Trial Summary
What is the purpose of this trial?
The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it mentions that participants should be on optimal medical therapy for heart failure according to current guidelines, which suggests you may need to continue your existing heart failure medications.
What data supports the effectiveness of the treatment His-Bundle vs Biventricular Pacing for Heart Failure?
Is His-bundle pacing safe compared to biventricular pacing for heart failure?
How does His-bundle pacing differ from biventricular pacing for heart failure treatment?
Research Team
Roderick Tung, MD
Principal Investigator
University of Arizona
Valentina Kutyifa, MD, PhD
Principal Investigator
University of Rochester
Eligibility Criteria
This trial is for heart failure patients with right bundle branch block who meet specific criteria: they have certain levels of heart function and symptoms, are at least 18 years old, and follow optimal medical therapy. It's not for those with left bundle branch block, other ECG issues, or a life expectancy under one year.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) or cardiac resynchronization therapy (BIV-CRT)
Follow-up
Participants are monitored for changes in left ventricular ejection fraction, ECG biomarkers, NT-proBNP levels, and echocardiography biomarkers
Treatment Details
Interventions
- BIV-CRT
- His-CRT
BIV-CRT is already approved in European Union, United States for the following indications:
- Heart failure with reduced ejection fraction (LVEF ≤35%) and left bundle branch block (LBBB)
- Heart failure with reduced ejection fraction (LVEF ≤35%) and wide QRS
- Heart failure with reduced ejection fraction (LVEF ≤35%) and left bundle branch block (LBBB)
- Heart failure with reduced ejection fraction (LVEF ≤35%) and wide QRS
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
National Institutes of Health (NIH)
Collaborator